✦ LIBER ✦

Risk factors for peristomal pyoderma gangrenosum complicating inflammatory bowel disease

✍ Scribed by Wu, Xian-rui; Mukewar, Saurabh; Kiran, Ravi P.; Remzi, Feza H.; Hammel, Jeffery; Shen, Bo

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adalimumab for pyoderma gangrenosum asso

✍ Irune Cariñanos; Manuel Barreiro-De Acosta; Eugeni Domènech 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 50 KB 👁 1 views

Predictive factors for erythema nodosum

✍ Ampuero, Javier; Rojas-Feria, María; Castro-Fernández, Manuel; Cano, Cristina; R 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 541 KB

Infliximab for treatment of pyoderma gan

✍ Miguel Regueiro; John Valentine; Scott Plevy; Mark R Fleisher; Gary R Lichtenste 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 123 KB

Successful treatment with infliximab for

✍ Hiroaki HAYASHI; Chiaki KUWABARA; Kenichi TARUMI; Eiichi MAKINO; Wataru FUJIMOTO 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 365 KB

Homocysteine in inflammatory bowel disea

✍ Bas Oldenburg; Rob Fijnheer; René van der Griend; Gerard P vanBerge-Henegouwen; 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 86 KB

The Role of Anti-Tumor Necrosis Factor-α

✍ Z. Reguia??; F. Grange 📂 Article 📅 2007 🏛 Adis International Limited (now part of Wolters Kl 🌐 English ⚖ 269 KB